Expanding Access to HIV Testing: The Rise of Self-Testing in Resource-Limited Settings
Facing potential reductions in funding for traditional HIV prevention programs, global health experts at the International AIDS Society (IAS) 2025 meeting in Kigali, Rwanda, are increasingly advocating for the widespread adoption of HIV self-testing (HST). This approach offers a crucial pathway to maintain progress in both treatment and prevention efforts, especially in regions with constrained healthcare infrastructure.
The Strategic Importance of Self-Testing
Cheryl Johnson,a technical officer on HIV testing services at the World Health Organization (WHO),emphasized the urgency of integrating HST into standard healthcare delivery. She highlighted that a robust foundation for self-testing already exists, and now is the time for decisive action. This sentiment reflects a growing recognition that HST can circumvent barriers to access, such as geographical limitations, stigma, and limited clinic hours – factors that disproportionately effect vulnerable populations.
Consider the situation in many sub-Saharan African countries, where healthcare facilities are often concentrated in urban areas, leaving rural communities underserved. HST can bridge this gap, bringing testing directly to individuals in their homes or communities. According to UNAIDS, an estimated 1.3 million new HIV infections occurred in 2022,with the majority concentrated in sub-Saharan Africa.Expanding access to testing, through methods like self-testing, is thus paramount to curbing this epidemic.
Navigating Nuances: HST and Long-Acting PrEP
Despite the strong endorsement of HST,the WHO’s position isn’t uniformly positive across all preventative strategies. Michelle Rodolph, also a technical officer at WHO focusing on HIV prevention, revealed that HST was not included in the forthcoming guidelines for twice-yearly lenacapavir injections – a promising new long-acting injectable pre-exposure prophylaxis (PrEP). The guidelines rather prioritize rapid diagnostic tests.
Rodolph clarified that this exclusion stemmed from a lack of sufficient evidence to support a recommendation for HST specifically within the context of long-acting injectable PrEP. This highlights a critical point: while HST is valuable, its effectiveness needs to be rigorously evaluated for each specific request and population. The need for confirmatory testing and linkage to care following a positive self-test result remains a key consideration, particularly when initiating long-term preventative measures like injectable PrEP.
Real-World Impact and Cost-Effectiveness
Recent research presented at the IAS meeting further underscored the potential benefits of HST.A multi-contry study led by Brooke Nichols of Boston University School of Public Health, analyzed data from South africa, Zambia, Kenya, uganda, and Lesotho. The results indicated that HST led to an increase of 0.6 to 6 additional HIV-positive diagnoses per 100 tests distributed.Notably, Kenya was the only country in the study that demonstrated a significant increase in the initiation of antiretroviral therapy following self-testing.
Furthermore, Nichols’ research, detailed in a conference poster, suggests that HST can generate cost savings and alleviate pressure on already strained healthcare systems. Johnson echoed this point, stating that emerging data from across africa demonstrates the cost-effectiveness of HST, making it a particularly attractive option when healthcare capacity is limited. This is especially relevant given the global economic challenges and potential for future funding cuts.
In essence, the conversation surrounding HST at IAS 2025 isn’t simply about finding an option to traditional testing methods; it’s about strategically leveraging a powerful tool to maximize impact and ensure continued progress towards ending the HIV epidemic.